Cambrex

Cambrex is a small molecule company that offers drug substance, drug product, and analytical services. The company provides an end-to-end partnership for the research, development, and manufacture of small molecule therapeutics at every stage of the lifecycle. With years of experience and a growing team of experts servicing global clients, the company is tried and trusted in branded and generic markets for API and dosage form development and manufacturing.  It was founded on 1981 and is headquartered in East Rutherford, New Jersey.

BENSHEIM, Germany--( BUSINESS WIRE )--Simple treatments can protect people from Neglected Tropical Diseases (NTDs), which, if left untreated, lead to disabilities, including blindness and disfiguration. Christian Blind Mission (CBM) recently celebrated the milestone of the 600 millionth dose of medicines to protect communities from NTDs. Ten-year-old Surayya in Nigeria was the recipient of this historic dose and is now protected. But more needs to be done: On the occasion of the World Neglected Tropical Diseases Day (30 January), CBM reaffirms its commitment to stay the course and calls on partners to join them in the fight against NTDs.

CBM Distributes 600 Millionth Drug Dose to Protect Against Neglected Tropical Diseases

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks' biosimulation platform and Computational Biology Model (CBM) to predict responses to pharmaceutical interventions in silico, thereby streamlining the clinical trial process by identifying the right patients more rapidly, which in turn reduces the time and expense of developing successful pharmaceutical agents.

Cellworks Expands Into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

EAST RUTHERFORD, N.J., Oct. 12, 2020 /PRNewswire/ -- Cambrex, announced today the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland. This major expansion project has seen the facility's total footprint doubled to...

Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh

EAST RUTHERFORD, N.J., April  07, 2020  (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site. Biopharmaceutical analysis services were initially launched at Durham in 2018 and have since been expanded through the purchase and implementation of various method development, validation, release and stability or endotoxin testing functions.

Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility

EAST RUTHERFORD, N.J., March  31, 2020  (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Troy Player has been appointed as President, Early Stage Development and Testing (ESDT). In his new role, he has responsibility for operations at the Agawam, Massachusetts; Durham, North Carolina; Edinburgh, UK; High Point, North Carolina and Longmont, Colorado facilities.

Cambrex Appoints Troy Player as President, Early Stage Development & Testing Business Unit

EAST RUTHERFORD, N.J., Jan.  06, 2020  (GLOBE NEWSWIRE) -- Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced changes to its management team and Board of Directors to accelerate growth and further operational excellence, building upon its trusted reputation for the highest quality pharmaceutical development and manufacturing capabilities.

Cambrex Announces Management Changes and Board Appointments

EAST RUTHERFORD, N.J., Dec.  04, 2019  (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced the completion of its previously announced sale to an affiliate of the Permira funds.

Cambrex Announces Completion of Acquisition by the Permira Funds

Alexion Pharma

ALXN vs. CBM: Which Stock Is the Better Value Option?

ALXN vs. CBM: Which Stock Should Value Investors Buy Now?

EAST RUTHERFORD, N.J., Nov.  14, 2019  (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has won the ‘Excellence in Pharma: API Development’ category at the annual CPhI Pharma Awards, which took place at a Gala Dinner at CPhI Worldwide in Frankfurt on November 5th. This marks the third time that Cambrex has won the category in the past 4 years, having previously won in 2016 and 2017. The Company was also judged ‘highly commended’ in the same category in 2018.

Cambrex Wins Third API Development Award at CPhI Worldwide

ALXN or CBM: Which Is the Better Value Stock Right Now?

EAST RUTHERFORD, N.J., Oct.  24, 2019  (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that in connection with the debt portion of the financing for the pending acquisition by an affiliate of the Permira Funds, they are making the following third quarter 2019 preliminary unaudited financial information available to prospective lenders. 

Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Results

EAST RUTHERFORD, N.J., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day “go shop” period under the previously announced Agreement and Plan of Merger, dated as of August 7, 2019 (the “Merger Agreement”), which provides for the Company to be acquired by an affiliate of the Permira funds in an all-cash transaction for $60.00 per share. At the direction of the ad hoc committee of the Company’s Board of Directors, the Company’s financial advisor engaged in solicitation of 77 potential bidders, which resulted in eight potential bidders each entering into a confidentiality agreement with the Company. Each of the eight parties that entered into a confidentiality agreement with the Company was provided access to nonpublic information regarding the Company and the opportunity to have access to Company management. As of the expiration of the go-shop period, the Company had not received any alternative acquisition proposals, including from any of the eight parties that entered into confidentiality agreements. Upon the expiration of the go-shop period and in accordance with the terms of the Merger Agreement, the Company became subject to customary “no-shop” restrictions on its ability to solicit acquisition proposals from third parties or to provide information to and engage in discussions with a third party in relation to an alternative acquisition proposal, subject to certain customary exceptions.

Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement

Cambrex (NYSE: CBM) shares are trading sharply higher after the company announced it will be acquired by the Permira Funds in a deal valued around $2.4 billion.

Permira Funds To Acquire Cambrex In $2.4B Deal

Shares of Cambrex Corp. CBM, +0.27% rocketed 47% in toward a 10-month high in premarket trading Wednesday, after drug product and analytical services company agreed to be acquired in a deal valued at $2.4 billion including debt by an affiliate of the private-equity firm Permira.

Cambrex stock rockets after $2.4 billion buyout deal at a 60% premium

Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cambrex (CBM) Q2 Earnings Expected to Decline

Bio-Techne

CBM vs. TECH: Which Stock Is the Better Value Option?

CBM or TECH: Which Is the Better Value Stock Right Now?

Ituran Location & Control

Littelfuse

MAXIMUS

Thor Industries

According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety.

5 Quality Stocks With Margin of Safety

Alkermes

CBM vs. ALKS: Which Stock Is the Better Value Option?

CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

Cambrex (CBM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Cambrex (CBM) Run Higher on Rising Earnings Estimates?

Cambrex Corporation (CBM) CEO Steven Klosk on Q1 2019 Results - Earnings Call Transcript

Cambrex (CBM) delivered earnings and revenue surprises of 17.65% and -0.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Cambrex Stock (CBM)